Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (30)

2024

  1. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

2021

  1. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer

    Molecular Oncology, Vol. 15, Núm. 4, pp. 887-900

  2. Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer

    Molecular Oncology, Vol. 15, Núm. 2, pp. 350-363

2020

  1. Epigenetic SmAd3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma

    Cancer Research, Vol. 80, Núm. 2, pp. 276-290

  2. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings

    Journal of Neurology, Vol. 266, Núm. 10, pp. 2396-2405

  3. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 360-369

2018

  1. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

2015

  1. Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma

    European Journal of Dermatology, Vol. 25, Núm. 5, pp. 392-403

2014

  1. Differential neuroprotective effects of 5′-deoxy-5′- methylthioadenosine

    PLoS ONE, Vol. 9, Núm. 3

  2. Dynamic molecular monitoring of retina inflammation by in vivo Raman spectroscopy coupled with multivariate analysis

    Journal of Biophotonics, Vol. 7, Núm. 9, pp. 724-734

  3. Guidelines for biomarker testing in metastatic melanoma: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 362-373

  4. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

  5. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis

    PLoS ONE, Vol. 9, Núm. 12

  6. Recomendaciones para la determinación de biomarcadores en el melanoma metastásico. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

    Revista Espanola de Patologia

2013

  1. Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity

    BMC Systems Biology, Vol. 7

2012

  1. Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus

    Molecular Genetics and Metabolism, Vol. 105, Núm. 3, pp. 525-527

  2. Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis

    Revista de Neurologia, Vol. 54, Núm. 2, pp. 114-124